Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic and structural analyses reveal the low potential of the SARS‐CoV‐2 EG.5 variant
Fabio Scarpa, Stefano Pascarella, Alessandra Ciccozzi, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 9
Open Access | Times Cited: 10

Showing 10 citing articles:

Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion
Song Xue, Yuru Han, Fan Wu, et al.
Protein & Cell (2024) Vol. 15, Iss. 6, pp. 403-418
Open Access | Times Cited: 12
EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19
Abdolreza Esmaeilzadeh, Fereshteh Ebrahimi, Armin Jahani Maleki, et al.
Infection (2024) Vol. 52, Iss. 2, pp. 337-343
Closed Access | Times Cited: 7
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial
Jihai Tang, Qinghua Xu, C. Zhu, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 175-175
Open Access | Times Cited: 3
SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies
Hailong Guo, Sha Ha, Jason Botten, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 697-697
Open Access | Times Cited: 3
Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact
Debayan Sil, Shreastha Gautam, Shubhi Saxena, et al.
Current Drug Targets (2024) Vol. 25, Iss. 8, pp. 517-525
Closed Access | Times Cited: 3
The mutation point of view of the SARS‐CoV‐2 HV.1 lineage
Alessandra Ciccozzi, Pier Luigi Fiori, Marco Casu, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Closed Access | Times Cited: 2
On the SARS-CoV-2 Variants
Fabio Scarpa, Francesco Branda, Nicola Petrosillo, et al.
Infectious Disease Reports (2024) Vol. 16, Iss. 2, pp. 289-297
Open Access | Times Cited: 2
Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency
Haoran Zhang, Kangping Zhou, Fei Peng, et al.
Journal of Infection (2024) Vol. 88, Iss. 2, pp. 211-214
Open Access | Times Cited: 1
COVID -19: On the threshold of the fifth year. The situation in Spain
Fernando Rodríguez‐Artalejo, Julián Ruiz‐Galiana, Rafael Cantón, et al.
Revista Española de Quimioterapia (2023) Vol. 37, Iss. 1, pp. 17-28
Open Access | Times Cited: 3
Immunogenicity of Tetravalent Protein Vaccine, SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: a Phase 2 Trial
Jihai Tang, Qinghua Xu, C. Zhu, et al.
(2023)
Open Access | Times Cited: 3
Page 1

Scroll to top